Venture capital firm Andreessen Horowitz said on Friday it was working with Eli Lilly to launch a $500 million venture fund that will be fully funded by the U.S. drugmaker.
Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.
Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.
Pharmaceutical stocks represent an interesting prospect — while it is incredibly tough to separate the wheat from the chaff, picking a winner early on is more or less a ticket to outsized returns.
In the latest trading session, Eli Lilly (LLY) closed at $773.29, marking a +1.07% move from the previous day.
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug Administration over the agency's decision that Lilly's blockbuster weight-loss and diabetes drugs are no longer in short supply.
R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), AbbVie (ABBV), AstraZeneca (AZN) and Pfizer (PFE) are worth retaining in one's portfolio.
It hasn't been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.
Eli Lilly (LLY) reachead $773.84 at the closing of the latest trading day, reflecting a -1.19% change compared to its last close.
Stocks splits have been a huge market theme in 2024, with big names across industries, from technology giant Nvidia to consumer stock Walmart completing such operations. Companies often launch this move after a long period of gains as a way to make their stock price more accessible to a wide range of investors.
If you're looking for top stocks, there's no need to reinvent the wheel. The Securities and Exchange Commission makes it a breeze to follow the world's greatest investors.